The startup specializes in drug discovery technology that targets e3 ligase ligands, which play a critical role in the development of inflammatory diseases. By focusing on conditions such as neuropathic pain and chronic obstructive pulmonary disease, the company aims to provide effective treatments for various unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Many inflammatory diseases lack effective treatments due to the complex nature of the inflammatory cascade and the difficulty in selectively modulating key protein interactions. Current approaches often fail to address the root cause of inflammation, leading to limited efficacy and potential side effects.
Solution
Koutif Therapeutics is developing therapeutic compounds that uniquely inhibit the inflammatory cascade by targeting Fbxo3, an E3 ligase that negatively regulates the degradation of pro-inflammatory proteins. Their medicinal chemistry strategy is based on the discovery that inhibiting Fbxo3 allows for the degradation of TRAFs and the NLRP3 inflammasome, key proteins involved in adaptive and innate immune signaling pathways. This mechanism has the potential to treat numerous inflammatory conditions by restoring the natural regulation of the inflammatory response. Koutif's approach aims to provide a more targeted and effective treatment for a variety of inflammatory diseases.
Target Audience
The primary target audience includes pharmaceutical companies seeking novel drug candidates for inflammatory diseases and research institutions focused on immunology and drug discovery.
Features
- Focus on inhibiting Fbxo3, a novel and previously untargeted E3 ligase
- Promotes the degradation of TRAFs and the NLRP3 inflammasome
- Aims to modulate adaptive and innate immune signaling pathways
- Based on intellectual property licensed from the University of Pittsburgh and the United States Department of Veterans Affairs